As Galectin-9 is specifically expressed by NPC cells, the TIM3/Galectin-9 interaction represents a promising approach to overcoming the resistance to the PD-1/PD-L1 inhibitors. The gene discussed is HAVCR2; the disease is nasopharyngeal carcinoma.